Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Capital Health Regional Medical Center
mi
from
Trenton, NJ
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Capital Health Regional Medical Center
mi
from
Trenton, NJ
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
The Long Island Brain Tumor Center at Neurological Surgery, P.C.
mi
from
Lake Success, NY
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
The Long Island Brain Tumor Center at Neurological Surgery, P.C.
mi
from
Lake Success, NY
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
North Shore University Hospital
mi
from
Manhasset, NY
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Columbia University Medical Center
mi
from
New York, NY
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Mount Sinai Hospital
mi
from
New York, NY
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
New York University Clinical Cancer Center
mi
from
New York, NY
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
New York University Clinical Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Univ of Rochester Medical Center
mi
from
Rochester, NY
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Stony Brook Medicine
mi
from
Stony Brook, NY
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Stony Brook Medicine
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Brain and Spine Surgeons of New York and Northern Westchester Hospital
mi
from
White Plains, NY
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Brain and Spine Surgeons of New York and Northern Westchester Hospital
mi
from
White Plains, NY
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Wake Forest Baptist Medical Center
mi
from
Winston-Salem, NC
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Wake Forest Baptist Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
University of Cincinnati Cancer Institute
mi
from
Cincinnati, OH
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
University of Cincinnati Cancer Institute
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Ohio State University
mi
from
Columbus, OH
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Oklahoma University Health Science Center
mi
from
Oklahoma City, OK
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Oklahoma University Health Science Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Geisinger Medical Center
mi
from
Danville, PA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Jefferson Hospital for Neuroscience
mi
from
Philadelphia, PA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Jefferson Hospital for Neuroscience
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Temple University School of Medicine
mi
from
Philadelphia, PA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Temple University School of Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Rhode Island Hospital
mi
from
Providence, RI
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Medical University of South Carolina Hospitals and Clinics
mi
from
Charleston, SC
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Medical University of South Carolina Hospitals and Clinics
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Saint Thomas Research Institute, LLC
mi
from
Nashville, TN
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Saint Thomas Research Institute, LLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Baylor Research Institute
mi
from
Dallas, TX
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Baylor Research Institute
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Cancer Therapy & Research at University of Texas Health Science Center San Antonio
mi
from
San Antonio, TX
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Cancer Therapy & Research at University of Texas Health Science Center San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Benaroya Research Institute at Virginia Mason
mi
from
Seattle, WA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Benaroya Research Institute at Virginia Mason
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Swedish Hospital Neuroscience Research
mi
from
Seattle, WA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Swedish Hospital Neuroscience Research
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Aurora Saint Lukes Medical Center
mi
from
Milwaukee, WI
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Aurora Saint Lukes Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
City of Hope
mi
from
Duarte, CA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
University of Colorado Cancer Center
mi
from
Aurora, CO
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Moffitt Cancer Center
mi
from
Tampa, FL
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
The Valley Hospital
mi
from
Ridgewood, NJ
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
The Valley Hospital
mi
from
Ridgewood, NJ
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
OhioHealth
mi
from
Columbus, OH
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
OhioHealth
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Methodist Hospital
mi
from
Houston, TX
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Montreal Neurological Institute, McGill University
mi
from
Montreal,
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Montreal Neurological Institute, McGill University
mi
from
Montreal,
Click here to add this to my saved trials
68Ga-DOTATATE PET Scan in Neuroendocrine Cancer
Use of 68Ga-DOTATATE PET Scanning for Diagnosis and Treatment of Metastatic Neuroendocrine Tumors
Status: Enrolling
Updated:  2/25/2016
Vanderbilt University Medical Center
mi
from
Nashville, TN
68Ga-DOTATATE PET Scan in Neuroendocrine Cancer
Use of 68Ga-DOTATATE PET Scanning for Diagnosis and Treatment of Metastatic Neuroendocrine Tumors
Status: Enrolling
Updated: 2/25/2016
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Boston, MA
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Detroit, MI
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Nashville, TN
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  2/25/2016
Research Site
mi
from
Barcelona,
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 2/25/2016
Research Site
mi
from
Barcelona,
Click here to add this to my saved trials
Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin
BrUOG 300: Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin
Status: Enrolling
Updated:  2/25/2016
Rhode Island Hospital (including Newport Hospital and East Greenwich)
mi
from
Providence, RI
Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin
BrUOG 300: Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin
Status: Enrolling
Updated: 2/25/2016
Rhode Island Hospital (including Newport Hospital and East Greenwich)
mi
from
Providence, RI
Click here to add this to my saved trials
Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin
BrUOG 300: Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin
Status: Enrolling
Updated:  2/25/2016
Miriam Hospital
mi
from
Providence, RI
Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin
BrUOG 300: Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin
Status: Enrolling
Updated: 2/25/2016
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Chemotherapy and Hormone Therapy in Treating Patients With Prostate Cancer
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Definitive Local Treatment
Status: Enrolling
Updated:  2/25/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Chemotherapy and Hormone Therapy in Treating Patients With Prostate Cancer
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Definitive Local Treatment
Status: Enrolling
Updated: 2/25/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Chemotherapy and Hormone Therapy in Treating Patients With Prostate Cancer
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Definitive Local Treatment
Status: Enrolling
Updated:  2/25/2016
Lahey Clinic - Burlington
mi
from
Burlington, MA
Chemotherapy and Hormone Therapy in Treating Patients With Prostate Cancer
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Definitive Local Treatment
Status: Enrolling
Updated: 2/25/2016
Lahey Clinic - Burlington
mi
from
Burlington, MA
Click here to add this to my saved trials
Chemotherapy and Hormone Therapy in Treating Patients With Prostate Cancer
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Definitive Local Treatment
Status: Enrolling
Updated:  2/25/2016
University of Massachusetts Memorial Medical Center - University Campus
mi
from
Worcester, MA
Chemotherapy and Hormone Therapy in Treating Patients With Prostate Cancer
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Definitive Local Treatment
Status: Enrolling
Updated: 2/25/2016
University of Massachusetts Memorial Medical Center - University Campus
mi
from
Worcester, MA
Click here to add this to my saved trials
Chemotherapy and Hormone Therapy in Treating Patients With Prostate Cancer
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Definitive Local Treatment
Status: Enrolling
Updated:  2/25/2016
Norris Cotton Cancer Center
mi
from
Lebanon, NH
Chemotherapy and Hormone Therapy in Treating Patients With Prostate Cancer
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Definitive Local Treatment
Status: Enrolling
Updated: 2/25/2016
Norris Cotton Cancer Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer
A Randomized Phase II Trial of Docetaxel With or Without Bevacizumab as First-Line Therapy for Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  2/25/2016
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer
A Randomized Phase II Trial of Docetaxel With or Without Bevacizumab as First-Line Therapy for Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 2/25/2016
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials